Takeda Pharmaceutical Co. Ltd.’s oral TYK2 inhibitor zasocitinib (TAK-279) demonstrated statistical superiority over Bristol Myers Squibb Co.’s first-in-class Sotyktu (deucravacitinib) in a top-line phase III Latitude Atlas readout of moderate to severe plaque psoriasis. Read More
With full phase II results in hand, MBX Biosciences Inc. backers are stacking the odds of parathyroid hormone (PTH) peptide prodrug canvuparatide (canvu) against Yorvipath (palopegteriparatide} from Ascendis Pharma A/S, a PTH analog cleared by the U.S. FDA in August 2024 for hypoparathyroidism (HP). Read More
Biopharma deal value through the first five months of 2026 reached $135.36 billion, outpacing every prior year and topping 2025’s previous high of $103.92 billion. May was the year’s biggest month so far at $41.78 billion in transactions, making it one of the strongest individual months on record, and far outpacing April’s $13.87 billion. May 2026 comes in third in recent years in terms of deal value, after October 2023’s $44.91 billion and December 2022’s $42.45 billion. Read More
Oricell Therapeutics Holdings Ltd.’s glypican-3 (GPC3)-targeted autologous CAR T therapy, Ori-C101, is heading into a confirmatory registration phase II trial in patients with GPC3-positive advanced hepatocellular carcinoma, positioning it as the first GPC3-directed immune cell therapy – and the first CAR T therapy for liver cancer – to reach that stage of development. Read More
The industry is in support of the EU Biotech Act but says it needs to go further to restore Europe’s competitive position in biopharma. Instead of incremental adjustments, there should be wide-ranging change to create a system that supports the full lifecycle of drug development, from academic research and clinical development, to manufacturing and commercialization. Read More
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into cancer cells,” Franck Bourdeaut told his audience at the 2026 Annual Congress of the European Hematology Association (EHA 2026). “On the contrary, in pediatric cancers, it is assumed that very few mutations are responsible for a maturation block, make these cells derail from their normal differentiation trajectory and ultimately result in an early onset typical pediatric cancer.” Read More
New hires and promotions in the biopharma and med-tech industries, including: Ambros, Aspen, Bighat, Dentsply, Fedora, Harbour, Oriva, Palisade, Phoremost, Poxel, Relmada, Viking, Vir. Read More
Biopharma and med-tech companies raising money in public or private financings, including: Atossa, Cequr, Edesa, Humacyte, Ideaya, Kardigan, Nyxoah, Thruflo. Read More
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron, Enliven, Glyconex, Humacyte, Imviva, Johnson & Johnson, Kura, Novartis, Nurix, Oryzon, Renovorx, Silence, Syndax, Takeda, Theriva, Vertex. Read More
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Amgen, Biontech, Chemocentryx, Chiesi, Emalex, Forus, Kalvista, Moderna, Pharmaessentia, Pfizer, Precision, Sanofi, Snke, Teva, Veraxa. Read More
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Camurus, Guardant, Karl Storz, Pharmaessentia, Roche, Wave. Read More
